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potential vascular, metabolic, and psychosocial
risk factors
Insa Feinkohl1*, Jackie F. Price1, Mark W.J. Strachan2 and Brian M. Frier3Abstract
Older people with type 2 diabetes are at increased risk of developing cognitive impairment, for which several potential
risk factors have been proposed. The present article reviews evidence in people with type 2 diabetes for associations of
cognitive impairment with a range of vascular, metabolic, and psychosocial risk factors, many of which have a higher
prevalence in people with type 2 diabetes than in non-diabetic adults of a similar age. Definitive research studies
in this field are few in number. The risk factors may be involved in causal pathways or may act as useful markers
of cerebrovascular damage (or both), and for which relatively consistent evidence is available, include poor glycemic
control, hypoglycemia, microvascular disease, inflammation, and depression. For macrovascular disease, the strength of
the association with cognitive impairment appears to depend on which vascular system has been examined. A role for
pre-morbid ability in young adulthood as influencing the risk of both diabetes and cognitive impairment has also been
suggested. The importance of considering inter-relationships between risk factors when investigating their potential
contribution to cognitive impairment in future investigations is discussed.Introduction
The global pandemic of diabetes is exerting an ever-
increasing burden on health-care systems. The incidence
of dementia is also rising worldwide. Diabetes, which is
characterized by chronic hyperglycemia, appears to be as-
sociated with an increased risk of developing Alzheimer’s
disease (AD) and vascular dementia (VaD), both in the
general population [1] and in people who have already
been diagnosed with a milder form of age-related cog-
nitive impairment (mild cognitive impairment) [2].
With cognitive aging as a continuum, people with type
2 diabetes have been found to experience accelerated
cognitive decline within a dementia-free range of between
20 % and 50 % [3], and recent reports have suggested a
role of mid-life (rather than late-life) diabetes in particular
in promoting this cognitive dysfunction [4, 5].
Numerous vascular, metabolic, and psychosocial factors
have a potential role in the development of cognitive im-
pairment in populations with diabetes and may contribute
to diabetes-related cognitive decline (Fig. 1). Most factors* Correspondence: ifeinkohl@gmail.com
1Centre for Population Health Sciences, Medical School, Teviot Place,
Edinburgh EH8 9AG, Scotland, UK
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creativecommons.org/publicdomain/zero/1.0/are inter-related and could influence cognitive ability
through a number of different pathophysiological path-
ways. In this article, we have aimed to provide an overview
(rather than a formal systematic review) of the current
evidence on risk factors for cognitive impairment in
people with diabetes. For that purpose, each risk factor
is considered individually and with a focus on prospective
epidemiological studies in populations with type 2 dia-
betes. Where such evidence is lacking, information derived
from studies in the general (non-diabetic) population and
from adults with type 1 diabetes has been included. It is
important to emphasize that even where associations
based on observational research are well established, these
do not demonstrate causality, and so evaluation of the
epidemiological evidence has been supplemented where
possible by consideration of intervention studies. Although
many of the risk factors are likely to affect cognition
through an influence on cerebrovascular disease, on AD-
typical pathology or on both, underlying pathophysiological
mechanisms are not the main focus of this article, and
these have been reviewed extensively elsewhere [6–8].
In addition, possible genetic factors are not addressed.article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Potential risk factors contributing to the increased risk of cognitive impairment in older adults with type 2 diabetes. AGE, advanced
glycation end-products; HPA, hypothalamic-pituitary axis. Adapted from [72]
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are summarized in Tables 1, 2, 3, 4 and are also provided
as supplemental data (Additional file 1).
Vascular and metabolic risk factors
Dyslipidemia
Although dyslipidemia is common in type 2 diabetes,
few observational studies have examined whether an as-
sociation exists between plasma lipid concentrations and
cognitive function (Table 1). Cognitive function has been
reported to be significantly poorer in people with type 2
diabetes who have elevated levels of plasma triglycerides
[9, 10] and in those with higher cholesterol levels [9],
but neither of these observations has been confirmed
[11, 12]. Two investigations even reported protective
effects: in one cross-sectional study, dislipidemia was
associated with better performance on a task of processing
speed [13], and higher total cholesterol was found to
decrease the risk of subsequent cognitive impairment
short of dementia during an 8-year period in the Fremantle
Diabetes Study [14]. However, a small intervention study
on the effects of physical exercise on insulin resistance over
a period of 12 weeks (which was unsuccessful in inducing a
change in insulin resistance) [15] and two further pro-
spective observational studies [16, 17] failed to find any
association between plasma lipid profiles and subsequent
cognitive decline or risk of impairment, with the exception
of an apparent association between lower mean high-density lipoprotein during a 6-year period and a steeper-
than-expected cognitive decline in a small Japanese study
during the same time period [16].
In the Action to Control Cardiovascular Risk in
Diabetes-Memory in Diabetes (ACCORD-MIND) random-
ized controlled trial (RCT), almost 3,000 older people with
type 2 diabetes were assigned either to intensive treatment
of hyperglycemia or to standard therapy [17]. Around 50 %
of participants also entered the only RCT to date to address
the effects of a reduction in plasma lipid levels on cognitive
decline in people with type 2 diabetes (the other 50 %
participated in a trial of anti-hypertensives). Despite a
greater reduction in cholesterol levels in patients who
received fenofibrate plus simvastatin compared with
those receiving placebo plus simvastatin, cognitive
function in the two groups declined at similar rates
during a 40-month follow-up period [17]. A review of
RCTs performed in the general (predominantly non-
diabetic) population also concluded that reducing plasma
cholesterol does not influence late-life cognitive function
[18], consistent with findings from observational studies
performed in the general population [2]. The role of
dyslipidemia in the development of cognitive impairment
in people with diabetes is therefore uncertain.
Hypertension
Hypertension is common in people with type 2 dia-
betes and, in general, has received more attention than
Table 1 Studies of dyslipidemia and cognitive function in type 2 diabetes
Study Sample Design Number Baseline mean
age
Lipids Cognitive measures Adjustment variables Association with cognitive
function
Bruce et al.
[14] (2008)
Patients with type 2
diabetes participating in
the Fremantle Diabetes
Study; Australia
8-year
retrospective,
observational
302 Mean 76 ±
5 years
Total cholesterol
and HDL at
baseline and
8 years earlier
Dementia and MCI identified
from screening instruments/
clinical interview
Waist-hip ratio No associations in unadjusted
cross-sectional or prospective
analyses. Higher total cholesterol
8 years earlier protective of cogni-
tive impairment short of dementia
(but not dementia or all cognitive
impairment) at baseline (finding in-
dependent of waist-hip ratio)
Chen et al.
[9] (2011)
Patients with type 2
diabetes; China
Cross-
sectional,
observational
101 Mean 63 ±
8 years
Total cholesterol,
LDL, and HDL
MCI identified on the basis of
cognitive screening instrument
None Higher triglycerides, total
cholesterol, and LDL in MCI
group compared with group free
of MCI. Negative correlation of
total cholesterol with scores on
cognitive screening instrument in
patients with MCI. No finding for
HDL.
Chen et al.
[11] (2012)
Patients with type 2
diabetes; China
Cross-
sectional,
observational
157 Mean 55 ±
7 years
Triglycerides,
total cholesterol,
LDL, and HDL
MCI identified on the basis of
cognitive screening instrument
None No association
Cukierman-
Yaffe et al.
[13] (2009)
Patients with type 2
diabetes participating in
ACCORD-MIND; North
America
Cross-
sectional
analysis of
trial on blood
pressure,
lipids, and
glycemic
control
2,977 Mean 63 ±
6 years
Hyperlipidemia
defined as use
of lipid-lowering
medication or
untreated LDL
cholesterol
Digit Symbol Coding (primary
outcome), MMSE, Rey Auditory
Verbal Learning, and Stroop
(secondary outcomes)
Age Association of hyperlipidemia
with better performance on Digit
Symbol Coding. No findings for
other cognitive tests.
Perlmutter
et al. [10]
(1988)
Patients with type 2
diabetes; USA
Cross-
sectional,
observational
246 Range 55-74
years
Triglycerides and
total cholesterol
Digit Symbol Coding, Digit Span,
and simple reaction time
Plasma glucose, HbA1c,
body mass index, and
history of hypertension
Lower cognitive function in ‘high’
compared with ‘low’ triglyceride
groups (fully adjusted analysis);
association of cholesterol with
triglyceride (unadjusted analysis).
Umegaki
et al. [16]
(2014)
Patients with type 2
diabetes; Japan
Six-year
prospective,
observational
79 Mean 74 ±
5 years
Mean of HDL
and LDL
measured at
baseline and
annual follow-
ups
Composite score from MMSE,
Digit Symbol Coding, Stroop,
and word recall. Analyses of
‘decliners’ versus ‘non-decliners’
on the basis of composite score
and individual cognitive tests.
Age, education, estimated
glomerular filtration rate,
renin-angiotensin system
inhibitor use, paraventricular
hyperintensities, and deep
white matter
hyperintensities
Lower mean 6-year HDL in
‘decliners’ compared with ‘non-
decliners’ on composite score
and Stroop (unadjusted analysis).
No finding for LDL. Mean 6-year
HDL significant predictor in
model of risk of decline on com
posite score (fully adjusted
analysis).
Williamson
et al. [17]
(2014)
Patients with type 2
diabetes participating in
ACCORD-MIND lipid
arm, receiving
40-month
trial on blood
pressure,
lipids, and
1,538 Mean 62 ±
6 years
Successful
manipulation of
cholesterol
levels (groups
Total brain volume at baseline
and 40 months, Digit Symbol
Coding (primary outcome),
MMSE, Rey Auditory Verbal
Glycemia treatment arm,
visit effect, clinical center,
and history of
cardiovascular disease
No difference in 20- or 40-month
cognitive decline or 40-month
change in total brain volume
Feinkohlet
al.A
lzheim
er's
Research
&
Therapy
 (2015) 7:46 
Page
3
of
21
Table 1 Studies of dyslipidemia and cognitive function in type 2 diabetes (Continued)
simvastatin + fenofibrate
or simvastatin + placebo;
North America
glycemic
control
differed on
cholesterol
following
intervention).
Learning, and Stroop (secondary
outcomes) at baseline and 20
and 40 months
between intervention and control
groups of lipid trial
Van Harten
et al. [12]
(2007)
Patients with type 2
diabetes; The
Netherlands
Cross-
sectional,
observational
92 Mean 73 ±
6 years
Total
cholesterol/HDL
ratio
Cognitive screening instruments,
composite scores of four
cognitive domains derived from
scores on battery of 10 cognitive
tests
Duration of diabetes,
HbA1c, insulin use,
hypertension, and
polyneuropathy
No association
Yanagawa
et al. [15]
(2011)
Patients with diabetes
receiving exercise
program four times per
week versus none;
Japan
12-week trial
on physical
exercise
intervention
16 Mean 71 ±
4 years
HDL and LDL
(no intervention
effect on HDL
and LDL)
MMSE, word recall, Digit Symbol
Coding, Stroop, and Trail-Making
Test
Age, education, and body
mass index
No difference in cognitive
function between treatment
groups following intervention
ACCORD-MIND, Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination
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Table 2 Studies of hypertension and cognitive function in type 2 diabetes
Study Sample Design Number Baseline mean
age
Blood pressure Cognitive measures Adjustment
variables
Association with cognitive
function
Chen et al.
[11] (2012)
Patients with type 2
diabetes; China
Cross-
sectional,
observational
157 Mean 55 ±
7 years
Hypertension defined on
the basis of systolic blood
pressure and diastolic
blood pressure
MCI identified on the basis of
cognitive screening instrument
None Higher prevalence of hypertension
in group with MCI compared with
group free of MCI. Negative
correlation of presence with
hypertension with cognitive scores.
No findings for blood pressure as
continuous measure.
Bruce et al.
[14] (2008)
Patients with type 2
diabetes
participating in the
Fremantle Diabetes
Study; Australia
8-year
retrospective,
observational
302 Mean 76 ±
5 years
Systolic blood pressure and
diastolic blood pressure at
baseline and 8 years earlier
Dementia and MCI identified from
screening instruments/clinical
interview
Age and
duration of
diabetes
Prospective analyses: higher
diastolic blood pressure 8 years
earlier associated with increased
risk of AD (but not MCI or any
dementia) at follow-up. No findings
in cross-sectional analyses.
Bruce et al.
[21] (2008)
Patients with type 2
diabetes
participating in the
Fremantle Diabetes
Study; Australia
8-year
retrospective,
2-year
prospective,
observational
205 Mean 75 ±
4 years
Systolic blood pressure and
diastolic blood pressure
measured 8 years prior to
baseline cognitive
assessment
Dementia and MCI identified from
screening instruments/clinical
interview at baseline and 2-year
follow-up. ‘Cognitive
decline’ defined as downward con-
version between ‘normal’, MCI, and
dementia.
None No association
Cukierman-
Yaffe et al.
[13] (2009)
Patients with type 2
diabetes
participating in
ACCORD-MIND;
North America
Cross-sectional
analysis of trial
on blood
pressure, lipids,
and glycemic
control
2,977 Mean 63 ±
6 years
Hypertension defined as
use of anti-hypertensive
medication or self-report of
hypertension
Digit Symbol Coding (primary
outcome), MMSE, Rey Auditory
Verbal Learning, and Stroop
(secondary outcomes)
Age Association of hypertension with
poorer performance on Digit
Symbol Coding. No findings for
other cognitive tests.
Hassing
et al. [19]
(2004)
OCTO-Twin Study of
people without
diabetes/
hypertension,
diabetes or
hypertension alone,
or co-morbid dia-
betes/
hypertension;
Sweden
6-year
prospective,
observational
258 Mean 83 ±
2 years
Hypertension defined as
use of anti-hypertensive
medication or on the basis
of systolic blood pressure
and diastolic blood pressure
from medical records
MMSE administered at baseline and
at 2-year intervals, dementia diag-
nosis prevalent at baseline, and in-
cident dementia diagnosis
Age, sex,
education,
smoking,
angina, MI, CHF,
stroke, and TIA
Co-morbid diabetes/hypertension
associated with steeper decline on
MMSE (compared with group free
of both conditions).
Statistically non-significant trend for
higher prevalence and
incidence of dementia in
co-morbid
diabetes/hypertension group
than in remaining groups.
Johnson
et al. [22]
(2012)
National cohort of
veterans with
diabetes; USA
2-year
retrospective,
observational
study of
hospital
records
377,838 Mean 76 ±
6 years
ICD codes for hypertension
at baseline (2 years before
analysis of incident
dementia)
ICD codes for incident dementia
diagnosis
Age, ethnicity,
geographic
area, duration
of diabetes,
co-morbidity
according to
HCC scores,
and medication
use
8 % increased risk of developing
dementia during follow-up in
patients with co-morbid
hypertension at baseline.
Decreased risk in patients on anti-
hypertensive medication (effect
size dependent on
medication), except for
increased risk in patients receiving
α-adrenoceptor blockers.
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Table 2 Studies of hypertension and cognitive function in type 2 diabetes (Continued)
Manschot
et al. [20]
(2006)
Patients with type 2
diabetes
participating in the
Utrecht Diabetic
Encephalopathy
Study; The
Netherlands
Cross-
sectional,
observational
122 Mean 66 ±
6 years
Hypertension defined on
the basis of systolic blood
pressure and diastolic
blood pressure or use of
anti-hypertensive
medication
Composite scores on five cognitive
domains from 11 cognitive tests,
estimate of pre-morbid ability, cor-
tical atrophy, and white matter
lesions
Age, sex, and
estimated pre-
morbid ability
Statistically non-significant trend
for lower scores on all cognitive
domains except memory in
patients with hypertension. Higher
blood pressure
associated with higher scores on
memory domain and with greater
severity of white matter lesions.
Manschot
et al. [25]
(2007)
Patients with type 2
diabetes
participating in the
Utrecht Diabetic
Encephalopathy
Study; The
Netherlands
Cross-
sectional,
observational
122 Mean 66 ±
6 years
Hypertension defined on
the basis of systolic blood
pressure and diastolic
blood pressure or use of
anti-hypertensive
medication
Composite score from 11 cognitive
tests, estimate of pre-morbid ability,
cortical atrophy, and white matter
lesions
Age, sex, and
estimated pre-
morbid ability
Statistically non-significant trend
for lower cognitive function in pa-
tients with hypertension (reaches
statistical significance in final
model including age,
estimated pre-morbid ability,
lipid-lowering drugs, and history of
any vascular event). Higher blood
pressure associated with greater se-
verity of white matter lesions.
Umegaki
et al. [16]
(2014)
Patients with type 2
diabetes; Japan
6-year
prospective,
observational
79 Mean 74 ±
5 years
Mean of systolic blood
pressure and diastolic
blood pressure measured at
baseline and annual follow-
ups
Composite score from MMSE, Digit
Symbol Coding, Stroop, and word
recall. Analyses of ‘decliners’ versus
‘non-decliners’ on bases of
composite score and individual
cognitive tests.
None No association
Williamson
et al. [17]
(2014)
Patients with type 2
diabetes
participating in
ACCORD-MIND
blood
pressure arm, with
systolic blood pres-
sure goal of 120 ver-
sus 140 mmHg;
North America
40-month
trial on blood
pressure,
lipids, and
glycemic
control
1,439 Mean 62 ±
6 years
Successful manipulation of
blood pressure (groups
differed on blood pressure
following intervention)
Total brain volume at baseline and
40 months, Digit Symbol Coding
(primary outcome), MMSE, Rey
Auditory Verbal Learning, and
Stroop (secondary outcomes) at
baseline and 20 and 40 months
Glycemia
treatment arm,
visit effect,
clinical center,
and history of
cardiovascular
disease
No difference in 20- or 40-month
cognitive decline treatment and
control groups. Greater reduction
in total brain volume in
intervention than in control group.
ACCORD-MIND, Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes; AD, Alzheimer’s dementia; CHF, congestive heart failure; HCC, Centers for Medicare and Medicaid Services’ Hierarchical Condition
Categories; ICD, International Classification of Diseases; MCI, mild cognitive impairment; MI, myocardial infarction; MMSE, Mini-Mental State Examination; OCTO-Twin Study, Origin of Variance in the Old Old Study:
Octogenarian Twins; TIA, transient ischemic attack
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Table 3 Studies of hyperglycemia or hyperinsulinemia and cognitive function in type 2 diabetes
Study Sample Design Number Baseline mean
age
Hyperglycemia/
hyperinsulinemia
Cognitive measures Adjustment variables Association with cognitive
function
Abbatecola
et al. [30]
(2006)
Patients with
diabetes free of
vascular disease,
receiving
repaglinide or
glibenclamide; Italy
12-month
trial on
glycemic
control
156 Mean 74 ±
2 years
Variation in post-prandial
blood glucose, fasting plasma
glucose, and HbA1c. (No dif-
ference between groups in
reduction of HbA1c and
plasma glucose during trial.
Decline in variation in post-
prandial glucose only in group
treated with repaglinide.)
Composite score of attention/
executive function (Trail-Making
Test, Digit Span, and verbal
fluency), MMSE, cortical atrophy,
and white matter lesions
Age, education,
physical activity,
depression, blood
pressure, cIMT, insulin
resistance, and body
mass index
Association of higher variation
in fasting plasma glucose and
post-prandial blood glucose
with lower cognitive function
across groups at baseline
(fully adjusted analyses).
Composite score and MMSE
declined in glibenclamide
but not in repaglinide group
during trial (analyses controlling
only for HbA1c and variation in
fasting plasma glucose).
Bruce et al.
[14] (2008)
Patients with type 2
diabetes
participating in the
Fremantle Diabetes
Study; Australia
8-year
retrospective,
observational
302 Mean 76 ±
5 years
HbA1c at baseline and 8 years
earlier
Dementia and MCI identified
from screening instruments/
clinical interview
None No association
Bruce et al.
[21] (2008)
Patients with type 2
diabetes
participating in the
Fremantle Diabetes
Study; Australia
8-year
retrospective,
2-year pro-
spective,
observational.
205 Mean 75 ±
4 years
HbA1c 8 years prior to
baseline cognitive assessment
Dementia and MCI identified
from screening instruments/
clinical interview at baseline
and at 2-year follow-up. ‘Cog-
nitive decline’ defined as
downward conversion between
‘normal’, MCI, and dementia.
None No association
Chen et al.
[9] (2011)
Patients with type 2
diabetes; China
Cross-
sectional,
observational
101 Mean 63 ±
8 years
HbA1c MCI identified on the basis of
cognitive screening
instrument
None Higher HbA1c in group with
MCI compared with group
free of MCI
Chen et al.
[11] (2012)
Patients with type 2
diabetes; China
Cross-
sectional,
observational
157 Mean 55 ±
7 years
HbA1c MCI identified on the basis of
cognitive screening
instrument
None No association
Cukierman-
Yaffe et al.
[13] (2009)
Patients with type 2
diabetes
participating in
ACCORD-MIND;
North America
Cross-
sectional
analysis of
trial on blood
pressure,
lipids, and
glycemic
control
2,977 Mean 63 ±
6 years
HbA1c and fasting plasma
glucose
Digit Symbol Coding (primary
outcome), MMSE, Rey
Auditory Verbal Learning, and
Stroop (secondary outcomes)
Total of 18
demographic and
clinical risk factors
Higher HbA1c associated with
lower Digit Symbol Coding.
Findings for other cognitive
tests did not survive full
adjustment. No findings for
fasting plasma glucose.
Launer
et al. [28]
(2011)
Patients with type 2
diabetes
participating in
ACCORD-MIND trial,
with HbA1c targets
of <6.0 % versus
7.0 % to 7.9 %;
North America
40-month
trial on blood
pressure,
lipids and
glycemic
control
2,977 Mean 62 ±
6 years
Successful manipulation of
glycemic control. (Treatment
groups differed in glycemic
control following
intervention.)
Total brain volume and
abnormal white matter at
baseline and 40 months. Digit
Symbol Coding (primary
outcome), MMSE, Rey
Auditory Verbal Learning, and
Stroop (secondary outcomes)
at baseline and 20 and
40 months.
Second trial
assignment (lipid or
blood pressure trials),
group allocation within
second trial
assignment, clinical
center, and history of
cardiovascular disease
No difference in 20- or 40-
month cognitive decline be-
tween intervention groups (fully
adjusted analyses). Total brain
volume declined at slower rate
in intensively treated compared
with standard treatment groups
(independent of adjustment
variables and of age, sex,
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Table 3 Studies of hyperglycemia or hyperinsulinemia and cognitive function in type 2 diabetes (Continued)
duration of diabetes, Digit
Symbol Coding). Greater
abnormal white matter in
intensively treated compared
with standard treatment group
at 40 months.
Manschot
et al. [20]
(2006)
Patients with type 2
diabetes
participating in the
Utrecht Diabetic
Encephalopathy
Study; The
Netherlands
Cross-
sectional,
observational
122 Mean 66 ±
6 years
HbA1c Composite scores on five
cognitive domains from 11
cognitive tests, estimate of
pre-morbid ability, cortical
atrophy, and white matter
lesions
Age, sex, and
estimated pre-morbid
ability
Association of higher HbA1c
with steeper estimated
lifetime decline in processing
speed. No association of
HbA1c with brain imaging
data.
Manschot
et al. [25]
(2007)
Patients with type 2
diabetes
participating in the
Utrecht Diabetic
Encephalopathy
Study; The
Netherlands
Cross-
sectional,
observational
122 Mean 66 ±
6 years
HbA1c and plasma insulin Composite score from 11
cognitive tests, estimate of
pre-morbid ability, cortical
atrophy, and white matter
lesions
Age, sex, and
estimated pre-morbid
ability
Association of higher HbA1c
with steeper estimated
lifetime decline in overall
cognitive function.
Association of higher insulin
with greater severity of white
matter lesions.
Ravona-
Springer
et al. [27]
(2014)
Patients with type 2
diabetes
participating in the
Israel Diabetes and
Cognitive Decline
Study; Israel
12-year
retrospective
observational
835 Mean 73 ±
5 years
Data on HbA1c from diabetes
register (mean 18 ± 10
measurements per patient).
Six HbA1c trajectories
identified (for example, high/
increasing and high/stable).
Measured at 12 years only:
CDR, MMSE, and battery of
seven cognitive tests. Sum of
z-scores calculated for four
cognitive domains.
Age, sex, education,
cardiovascular disease,
years in diabetes
register, anti-diabetes
treatment, and
depression
Associations of HbA1c
trajectories with level of
overall cognitive function,
semantic categorization, and
executive function. Relatively
poorest cognitive function in
high/decreasing group and
high/increasing groups.
Relatively highest
performance in low/stable
group.
Ryan et al.
[29] (2006)
Patients with type 2
diabetes, receiving
rosiglitazone or
glibenclamide; USA
24-week trial 145 Mean 60 ±
1 years
Successful manipulation of
glycemic control and insulin
sensitivity. (Treatment groups
differed in fasting plasma
glucose and fasting serum
insulin following intervention.)
CANTAB, Digit Symbol
Coding, Rey Auditory Verbal
Learning, and estimate of
pre-morbid ability
Age, center, pre-
morbid ability, and
baseline measurement
of fasting plasma glu-
cose/insulin
Cognitive function improved
equally in both treatment
groups (fully adjusted
analysis). Correlation of
reduction in fasting plasma
glucose with improvements
in working memory across
groups (unadjusted analysis).
No finding for insulin.
Seaquist
et al. [41]
(2013)
Patients with type 2
diabetes
participating in
ACCORD-MIND, with
HbA1c targets of
less than 6.0 % ver-
sus 7.0 % to 7.9 %;
North America
40-month
trial on blood
pressure,
lipids, and
glycemic
control
2,977 Mean 62 ±
6 years
Treatment with insulin at
enrolment and during trial
Digit Symbol Coding at
baseline and 20 and
40 months
Total of 21
demographic, lifestyle,
and clinical covariates
Association of insulin use at
enrolment with lower
baseline cognitive function.
Loss of statistical significance
upon full adjustment. No
association of insulin use
during trial with 40-month
cognitive decline in standard
treatment group. Association
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Table 3 Studies of hyperglycemia or hyperinsulinemia and cognitive function in type 2 diabetes (Continued)
of insulin use with steeper
40-month cognitive decline
in intensive treatment group;
loss of statistical significance
upon full adjustment.
Umegaki
et al. [16]
(2014)
Patients with type 2
diabetes; Japan
6-year
prospective,
observational
79 Mean 74 ±
5 years
Mean of HbA1c and plasma
immunoreactive insulin at
baseline and annual follow-ups.
Composite score from MMSE,
Digit Symbol Coding, Stroop,
and word recall. Analyses of
‘decliners’ versus ‘non-decliners’
on bases of composite score
and individual cognitive tests.
None No associations for HbA1c or
insulin, except for higher
mean 6-year insulin in
‘decliners’ compared with
‘non-decliners’ on Stroop.
Yanagawa
et al. [15]
(2011)
Patients with
diabetes receiving
exercise program
four times/week
versus none; Japan
12-week trial
on physical
exercise
intervention
16 Mean 71 ±
4 years
HbA1c, fasting blood glucose,
GIR, MCR in euglycemic
clamp, and immunoreactive
insulin. (No intervention effect
on any of these
measurements.)
MMSE, word recall, Digit
Symbol Coding, Stroop, and
Trail-Making Test
Age, education, and
body mass index
No difference in cognitive
function between groups
following intervention. Across
groups, changes in HbA1c
and changes in GIR correlated
with changes in word recall.
Changes in fasting blood
glucose correlated with
changes in Trail-Making.
ACCORD-MIND, Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes; CANTAB, Cambridge Neuropsychological Test Automated Battery; CDR, Clinical Dementia Rating Scale; cIMT, carotid intima-media
thickness; GIR, glucose infusion rate; MCI, mild cognitive impairment; MCR, metabolic clearance rate; MMSE, Mini-Mental State Examination
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Table 4 Studies of hypoglycemia and cognitive function in type 2 diabetes
Study Sample Design Number Baseline
mean age
Hypoglycemia Cognitive measures Adjustment variables Association with cognitive
function
Aung et al.
[33] (2012)
Patients with type 2
diabetes
participating in the
Edinburgh Type 2
Diabetes Study;
Scotland
Cross-sectional,
observational
1,066 Mean 68
± 4 years
Baseline self-report of
history of SH (defined as
episode requiring
assistance)
MMSE, composite score
from seven cognitive tests,
and estimate of pre-
morbid ability
Age, sex, duration of
diabetes, anti-diabetes
medication, depression,
alcohol, smoking, blood
pressure, HbA1c, stroke, TIA,
MI, angina, and retinopathy.
Analyses of estimated life-
time decline additionally
adjusted for estimated
pre-morbid ability.
History of SH associated
with lower cognitive
function and steeper
estimated lifetime decline
(fully adjusted analyses).
Linear negative relationship
between number of
episodes of SH in the year
before cognitive testing
and cognitive function
(analysis controlling for age
and sex).
Bruce et al.
[14] (2008)
Patients with type 2
diabetes
participating in the
Fremantle Diabetes
Study; Australia
8-year retrospective,
observational
302 Mean 76
± 5 years
Hypoglycemia resulting in
coma or hospitalization,
self-reported at baseline
and 8 years earlier
Dementia and MCI
identified from screening
instruments/clinical
interview
None Cross-sectional analysis:
increased prevalence of
history of hypoglycemia in
groups with poorer
cognitive function. No
findings in prospective
analyses.
Bruce et al.
[21] (2008)
Patients with type 2
diabetes
participating in the
Fremantle Diabetes
Study; Australia
8-year retrospective, 2-
year prospective,
observational
205 Mean 75
± 4 years
Hypoglycemia resulting in
coma or hospitalization,
self-reported 8 years prior
to baseline cognitive
assessment
Dementia and MCI
identified from screening
instruments/clinical
interview at baseline and
at 2-year follow-up. ‘Cognitive
decline’ defined as down-
ward conversion between
‘normal’, MCI, and
dementia.
None No association
Bruce et al.
[34] (2009)
Patients with type 2
diabetes
participating in the
Fremantle Diabetes
Study; Australia
5-year prospective,
observational
302 Mean 76
± 5 years
1. Self-reported medical
assistance or unconsciousness
or both.
Dementia and MCI
identified from screening
instruments/clinical
interview. ‘All cognitive
impairment’ summarizes
groups of dementia and
MCI.
Based on preliminary
associations of covariates
with cognition, the
following adjustment
variables were selected for:
analyses of MCI: age, sex,
education, and
cardiovascular disease; for
analyses of dementia:
duration of diabetes and
peripheral arterial disease;
for analyses of all cognitive
impairment: cardiovascular
disease, peripheral arterial
disease, and duration of
diabetes.
Cross-sectional analyses:
presence of MCI and all
cognitive impairment
associated with history of
all three measures of
hypoglycemia (fully
adjusted analyses). No
finding for
dementia.Prospective
analyses: no association of
baseline history of
hypoglycemia and risk of
‘cognitive decline’ in
patients free of cognitive
impairment at baseline
(unadjusted). Increased risk
of first-ever incident HSH in
group with dementia at
baseline (adjusted for
insulin use, body mass
2. Episodes rated by
medical staff as ‘doctor-
verified’.3. Codes for
ambulance or emergency
treatment for
hypoglycemia in hospital
records (HSH).
‘Cognitive decline’ defined
as conversion between
unimpaired, MCI, and
dementia.
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Table 4 Studies of hypoglycemia and cognitive function in type 2 diabetes (Continued)
index, inability to self-
manage medication, and
history of severe
hypoglycemia). No finding
on risk of subsequent
hypoglycemia in patients
with MCI at baseline.
de Galan
et al. [35]
(2009)
Patients with type 2
diabetes
participating in
ADVANCE arm on
glycemic control,
receiving standard
target versus target
HbA1c ≤6.5 %;
Australia
5-year trial on effects of
intensified blood
pressure control and
intensified glycemic
control
11,140 Mean 66
± 6 years
Incident SH defined as
blood glucose <2.8 mmol/
L or symptoms consistent
with hypoglycemia with
absence of another cause
and requiring external
assistance. Incident mild
hypoglycemia defined as
self-treated episode.
At baseline and 2-year
intervals: MMSE followed
by clinical interview for
patients with MMSE <24
or suspected dementia.
‘Normal’ cognitive function
defined as MMSE ≥28;
‘mild dysfunction’ as
MMSE = 24-27; ‘severe
dysfunction’ as MMSE <24.
Additional use of MMSE as
continuous measure.
Age, sex, treatment arm,
education, duration of
diabetes, blood pressure,
hypertension, HbA1c,
cholesterol, body mass
index, macrovascular
disease, microvascular
disease, smoking, and
alcohol
Prospective analyses
(unadjusted): increased risk
of SH (but not any
hypoglycemia) in groups
with ‘mild dysfunction’ and
‘severe dysfunction’ (versus
‘normal’ group). For ‘severe
dysfunction’, but not ‘mild
dysfunction’, finding
survived full adjustment.
Each unit-lower baseline
MMSE score associated
with 10 % increased risk of
SH (adjusted for age, sex,
education, and treatment
group). Increased risk of
hypoglycemia in treatment
group with intensified
glycemic control, but finding
similar across cognitive
groups. No difference in
cognitive decline between
treatment groups.
Feinkohl
et al. [38]
(2014)
Patients with type 2
diabetes
participating in the
Edinburgh Type 2
Diabetes Study;
Scotland
4-year prospective,
observational
1,066 Mean 68
± 4 years
Self-reported history of
episode requiring
assistance at baseline
(prevalent SH) and during
follow-up (incident SH)
MMSE, composite score
from seven cognitive tests,
and estimate of pre-
morbid ability
Age, sex, cholesterol, blood
pressure, smoking, HbA1c,
TIA, stroke, MI, and angina
History of SH and incident
SH both associated with
lower cognitive function at
year 4 and with increased
rate of 4-year cognitive
decline. Incident SH associated
with steeper estimated life-
time decline. Baseline
lower cognitive function
predicted increased risk of
incident SH.
Launer
et al. [28]
(2011)
Patients with type 2
diabetes
participating in
ACCORD and
ACCORD-MIND,
with HbA1c targets
of less than 6.0 %
versus 7.0 % to
7.9 %; North
America
40-month trial on blood
pressure, lipids, and
glycemic control
2,977 Mean 62
± 6 years
(ACCORD-
MIND)
Increased risk of episode of
hypoglycemia requiring
medical assistance and of
episode of hypoglycemia
requiring any assistance in
treatment arm with
intensified glycemic
control in ACCORD
(n = 10,251)
Total brain volume at
baseline and 40 months.
Digit Symbol Coding
(primary outcome), MMSE,
Rey Auditory Verbal
Learning, and Stroop
(secondary outcomes) at
baseline and 20 and
40 months.
Second trial assignment
(lipid or blood pressure
trials), group allocation
within second trial
assignment, clinical center,
and history of
cardiovascular disease
No difference in 20- or 40-
month cognitive decline
between treatment groups
in ACCORD-MIND substudy
of ACCORD (fully adjusted
analyses). Total brain volume
declined at slower rate in
intensively treated compared
with standard treatment
group (independent of
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Table 4 Studies of hypoglycemia and cognitive function in type 2 diabetes (Continued)
adjustment variables, and
of age, sex, duration of
diabetes, and Digit Symbol
Coding score). Greater
abnormal white matter
in intensively treated
compared with standard
treatment group at
40 months.
Lin and
Sheu [40]
(2013)
Patients with
diabetes
(>45 years); Taiwan
3-year retrospective
ascertainment of
hypoglycemia.Dementia
ascertained in
subsequent 4 years
15,000 Mean 64
± 10 years
ICD codes for any
hypoglycemia from
inpatient and outpatient
medical records
ICD codes for dementia
from inpatient and
outpatient medical records
Age, sex, insulin use,
cardiovascular disease,
hypertension, ischemic
heart disease, chronic
kidney disease, and
cholesterol
Hypoglycemia associated
with increased risk of
subsequent dementia
diagnosis. Linear
relationship of number of
episodes with dementia
risk.
Punthakee
et al. [36]
(2012)
Patients with type 2
diabetes
participating in
ACCORD-MIND,
with HbA1c targets
of <6.0 % versus
7.0 % to 7.9 %;
North America
40-month trial on blood
pressure, lipids and
glycemic control
2,956 Mean 62
± 6 years
1. SH defined as self-
reported <2.8 mmol/L or
symptoms that resolved
with use of glucose or
similar.2. HMA defined as
episode requiring medical
assistance (hospitalization;
care in emergency
department/ by emergency
personnel). 3. HAA defined
as episode requiring any
assistance.
Digit Symbol Coding
(primary outcome), MMSE,
Rey Auditory Verbal
Learning, and Stroop
(secondary outcomes) at
baseline and 20 and
40 months
Age, education, language
of test administration,
depression, second trial
assignment (lipid or blood
pressure trials), group
allocation within second
trial assignment, duration
of diabetes, stroke, HbA1c,
ethnicity, body mass index,
peripheral neuropathy,
urine albumin-to-creatinine
ratio, and baseline use of
insulin
Cross-sectional analyses
(unadjusted): association of
history of HMA with lower
cognitive function at
baseline. Lower baseline
cognitive function
predicted increased risk of
first-ever HMA and HAA
(but not recurrent HMA or
HAA) during follow-up
across intervention groups
(fully adjusted analyses). As-
sociation between 20-
month cognitive decline
and risk of first-ever HMA
in subsequent 22 months
(finding restricted to group
scoring in lowest tertile of
Digit Symbol Coding at
baseline; analysis adjusted
only for second trial
assignment, group
allocation within second
trial assignment).
Whitmer
et al. [39]
(2009)
Patients with type 2
diabetes; USA
18-year retrospective,
observational
17,000 Mean 65
± 7 years
ICD codes for emergency
treatment or hospitalization
for hypoglycemia, 1980 to
2002; additional analysis of
1980 to 1985.
ICD codes for any
dementia in inpatient and
outpatient medical records
2003 to 2007; additional
analysis of 2005 to 2007.
Age, sex, education,
ethnicity, duration of
diabetes, anti-diabetes
treatment, duration of insulin
use, HbA1c, body mass index,
hyperlipidemia, count scores
of co-morbidity based on ICD
codes for hypertension, car-
diovascular disease, stroke,
and end-stage renal disease
In 5- and 18-year analyses:
hypoglycemia (versus
none) 1980 to 2002 or
1980 to 1985 associated
with increased risk of
subsequent dementia
(analyses of dementia 2003
to 2007). Association of ≥2
episodes of hypoglycemia
(but not of single episode
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Table 4 Studies of hypoglycemia and cognitive function in type 2 diabetes (Continued)
of hypoglycemia) versus
none with increased risk of
dementia in analysis of
dementia 2005 to 2007.
Findings similar for codes
of any hypoglycemia and
for episodes resulting in
hospitalization.
Yaffe et al.
[37] (2013)
Patients with
diabetes
participating in
Health ABC; USA
12-year prospective,
observational
783 Mean 74
± 3 years
Hospital records identifying
hypoglycemia as primary
or secondary diagnosis
related to hospitalization
during follow-up.
Participants cognitively
unimpaired at baseline.
Identification of dementia
cases on the basis of
hospital records showing
ICD codes for dementia as
primary or secondary
diagnosis related to
hospitalization, or
dementia medication on
medication inventory
during annual visit; MMSE
administered at 2-year
intervals.
Age, sex, education,
ethnicity, diabetes at
baseline, insulin use,
HbA1c, APOE e4 status,
baseline MMSE, MI, stroke,
and hypertension
Cross-sectional analysis
(unadjusted): association of
history of hypoglycemia
with lower cognitive
function. Prospective
analyses: hypoglycemia
associated with increased
risk of dementia (fully
adjusted analysis; survived
additional adjustment for
slope of MMSE over time).
Dementia associated with
increased risk of
hypoglycemia (analysis
adjusted for adjustment
variables, minus HbA1c and
APOE e4).
ACCORD-MIND, Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; APOE,
apolipoprotein; HAA, hypoglycemia needing any assistance; Health ABC, Health, Aging and Body Composition Study; HMA, hypoglycemia requiring medical assistance; HSH, health service use for hypoglycemia;
ICD, International Classification of Diseases; MCI, mild cognitive impairment; MI, myocardial infarction; MMSE, Mini-Mental State Examination; SH, severe hypoglycemia; TIA, transient ischemic attack
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cognitive impairment (Table 2). Cross-sectional studies
have revealed trends for increased prevalence of hyperten-
sion in patients with lower cognitive function [11, 13, 19,
20], but cross-sectional analyses of blood pressure as a
continuous measure have failed to identify similar associa-
tions [11, 14, 21]. On the other hand, some [14, 19, 22],
though not all [17, 21], prospective studies have found a
relationship between baseline blood pressure or hyperten-
sion and the subsequent risk of cognitive decline. In the
Fremantle Diabetes Study, higher baseline diastolic blood
pressure was associated with an increased risk of incident
AD after 8 years [14], and in an investigation of people
over 80 years of age, the coexistence of hypertension
appeared to exacerbate diabetes-related cognitive decline
during a 6-year follow-up and to increase the risk of
dementia [19]. Similarly, a retrospective study that ex-
amined the hospital records of almost 380,000 older
patients with diabetes showed that co-morbid hypertension
increased the 2-year risk of dementia; treatment with
anti-hypertensive medication (other than α-adrenoceptor
blockers, with which the risk of dementia was increased)
further diminished the risk of dementia by between 4 %
and 24 % depending on the precise type of drug used [22].
In contrast with these findings, the blood pressure trial of
the ACCORD-MIND study did not demonstrate a dif-
ference in cognitive decline over a period of 40 months
between a group of patients who received intensive
anti-hypertensive therapy and a group on conventional
treatment, despite the success of the trial in producing
a difference in blood pressure between the two treatment
groups [17]. However, a direct association between blood
pressure and cognitive decline was not explored. In the
general (non-diabetic) population, the results of observa-
tional studies and of RCTs investigating links between
hypertension and cognitive impairment have also, in the
main, been negative [2, 23]. Therefore, although hyperten-
sion causes cerebrovascular disease and, as such, represents
a good candidate for a cognitive risk factor, its role in the
development of cognitive decline during aging in either the
diabetic or non-diabetic population remains unproven.Hyperglycemia
Raised blood glucose levels within the non-diabetic or
pre-diabetic range have consistently been associated with
cognitive impairment, with the strength of the association
increasing with advancing age [24]. Given that diabetes is
characterized by persistently raised blood glucose levels, a
causative role for hyperglycemia in diabetes-associated
cognitive decline would seem likely. However, the findings
from cross-sectional analyses on the association of HbA1c
with cognitive function [9, 11, 13, 14, 20, 25] and cognitive
decline [14, 16, 21] in people with type 2 diabetes havebeen inconsistent (Table 3), potentially due to the different
ages of the study populations. Overall, the association of
type 2 diabetes with increased cognitive impairment
appears to be relatively weak before the age of 70 years,
provided that good glycemic control is maintained, and it
is only in older patients that cognitive decrements related
to chronic hyperglycemia become apparent [26]. More
recently, a retrospective analysis of a cohort of people with
type 2 diabetes, in whom 12-year data on HbA1c were
available from a diabetes register, showed that in addition
to increments in blood glucose levels over time, poor
glycemic control long-term predicted a lower level of
late-life cognitive function, despite a trend toward im-
proved glycemic control by intensifying therapy [27].
This is consistent with the evidence showing damaging
effects of mid-life diabetes on the risk of late-life cognitive
impairment [4, 5] and suggests that irreversible damage
may already have occurred to predispose people to cog-
nitive impairment by the time that aggressive glucose-
lowering treatment was commenced.
In one of a number of intervention studies, changes in
blood glucose levels due to physical exercise correlated
with changes in cognitive function [15]. The ACCORD-
MIND study also found a statistically non-significant
trend for decelerated decline in processing speed at
20 months in the group with intensive therapy for gly-
cemic control (who achieved relatively greater glycemic
control) as compared with the conventional treatment
group (with resulting poorer glycemic control), although
this difference was no longer apparent at 40 months
[28]. Two smaller trials of patients with type 2 diabetes
have reported significant associations between improved
glycemic control and cognitive function. In one, improve-
ments in glycemic control in both treatment groups due
to treatment with either rosiglitazone or glibenclamide
(glyburide) correlated with improvement in working
memory over a period of 24 weeks [29]. In another, a
reduction in post-prandial glucose excursions with
repaglinide was associated with a decline in cognitive
function over a period of 12 months compared with
subjects who received glibenclamide and did not show
such a change in glucose excursions; the decline in
HbA1c was of similar magnitude in the two treatment
groups, suggesting a specific role for post-prandial glucose
excursions [30]. Whereas overall a recent systematic
review combining the evidence from observational
studies and from RCTs concluded that both hypergly-
cemia and glucose excursions are weakly associated
with poorer cognitive function in people with type 2
diabetes [31], a meta-analysis restricted to RCTs sug-
gested that improvement in glycemic control was un-
related to cognitive decline [32], illustrating the need
for further evaluation of hyperglycemia as a potentially
modifiable cognitive risk factor.
Fig. 2 Relationship of severe hypoglycemia with cognitive decline in
the Edinburgh Type 2 Diabetes Study. Relationship of a self-reported
history of one or more episodes of severe hypoglycemia (SH) (defined as
requiring external help) prior to the baseline clinic of the Edinburgh Type
2 Diabetes Study with the subsequent decline on a composite measure
(‘g’) of cognitive ability during 4-year follow-up. Error bars show 95 %
confidence interval (n = 831). Based on [38]
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Few studies have investigated the effect of previous ex-
posure to recurrent hypoglycemia on cognitive function
in people with type 2 diabetes. Heterogeneity with
respect to how ‘hypoglycemia’ has been defined presents
a major problem for interpretation of results, with re-
corded events ranging from asymptomatic biochemical
hypoglycemia to severe disabling hypoglycemia (Table 4).
Cross-sectional analyses have reported an association
between a history of previous self-reported or medically
verified severe hypoglycemia, defined as any episode re-
quiring external help to effect recovery, and cognitive
impairment [14, 33, 34] but this could reflect lower
cognitive ability in people who go on to experience a
higher frequency of severe hypoglycemia. Indeed, in the
Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation
(ADVANCE) trial, which successfully manipulated the
level of glycemic control (intensive versus standard) in
patients with type 2 diabetes, each one-unit-lower score
on a cognitive screening instrument at baseline was as-
sociated with a 10 % greater risk of severe hypoglycemia
during follow-up [35]. A lower baseline cognitive function
and (for participants who had low processing speed at
baseline) a relatively steeper cognitive decline between
baseline and the 20-month assessment were also predict-
ive of an increase in the subsequent first-ever hospital ad-
mission to treat severe hypoglycemia in ACCORD-MIND,
and the group with low processing speed and declining
cognitive function had a higher cumulative incidence of
severe hypoglycemia over the 4 years of the study [36].
Finally, in two further prospective investigations, a
baseline diagnosis of dementia or a diagnosis during
the follow-up period in previously unimpaired participants
was associated with a two- to three-fold higher rate of
hospital admission for emergency medical treatment of
hypoglycemia during follow-up [34, 37].
Whether exposure to hypoglycemia precedes cognitive
decline and may even be a causal risk factor for this con-
dition is less clear. In the Edinburgh Type 2 Diabetes
Study (ET2DS) of more than 1,000 adults between 60
and 75 years of age, a history of severe hypoglycemia
was associated with lower cognitive function when the
estimated pre-morbid cognitive function before exposure
to hypoglycemia was compared with post-hypoglycemia
cognitive function, with evidence of an acceleration of
late-life cognitive decline that was independent of the
potential influence of further episodes of hypoglycemia
[38] (Fig. 2). However, these observations conflict with
the findings of the Fremantle Diabetes Study [21] and
with the evidence from RCTs. In ACCORD-MIND and
ADVANCE, cognitive function declined at similar rates
by 40 months and 5 years in patients in the intensive
treatment groups (in whom the incidences of hypoglycemiawere significantly higher) compared with those in the
standard treatment arms [28, 35]. However, in both of these
trials, the management of diabetes was manipulated to
attain pre-determined glycemic targets. It is plausible
that any detrimental effect of hypoglycemia was coun-
terbalanced by an improvement in cognitive function
occurring through specific beneficial effects of the
assigned intervention.
Two retrospective investigations [39, 40] have suggested
that a dose-response relationship may exist between the
frequency of exposure to severe hypoglycemia and the
subsequent risk of dementia. However, these studies relied
on hospital records, a suboptimal method of identifying
hypoglycemia, and the suggestion that exposure to a single
episode of hypoglycemia would induce dementia is
biologically implausible. In the observational analysis
of the Fremantle Diabetes Study, a history of severe
hypoglycemia failed to predict the 5-year risk of dementia
[34]. In the prospective Health Aging and Body Com-
position Study, participants with incident hypoglycemia
had a two-fold risk of subsequent dementia over a
period of 12 years, but in combination with the analysis
showing an increased risk of subsequent hypoglycemia
in patients who were diagnosed with dementia during
follow-up, the data were overall interpreted as showing
bidirectional causality [37]. It is essential that the role
of hypoglycemia in either causing or accelerating cogni-
tive decline be clarified in view of the current policy to
use intensive therapy to achieve near-normoglycemia to
minimize the development of diabetic complications.
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Hyperinsulinemia from endogenous hypersecretion of
insulin is common in the early stages of type 2 diabetes
as a ‘pathophysiological’ response to insulin resistance; it
also occurs as a consequence of exogenous insulin therapy.
Hyperinsulinemia has been associated with cognitive im-
pairment, but a systematic review of observational studies
that included people with and those without diabetes
concluded that the evidence for an association of elevated
plasma insulin concentrations with impairment of cogni-
tion was weak, because it is possible that any association
of plasma insulin with cognition in such samples had been
influenced by the inclusion of people with diabetes [24].
Very few studies have been performed in non-diabetic
populations or exclusively in people with type 2 diabetes
(Table 3). In one observational study, a higher mean insu-
lin during a 6-year period was associated with a steeper
rate of concurrent cognitive decline based on a test of ex-
ecutive function [16], and in a small intervention study,
which was unsuccessful in inducing a difference in insulin
sensitivity in two treatment groups through physical exer-
cise, improvement in memory performance correlated
with improvements in insulin resistance [15]. By contrast,
in a larger 24-week trial in middle-aged to older patients
with type 2 diabetes (mean age of 60 years), an improve-
ment in plasma insulin levels and insulin sensitivity had
no effect on concurrent change in cognitive function [29].
Similarly, in the ACCORD-MIND study, treatment
with insulin on study entry or during the trial was rela-
tively unrelated to 40-month cognitive change, but
plasma insulin levels as such were not considered [41].
This is despite the fact that compliance by participants is
difficult to ascertain. Inter-relationships between plasma
insulin concentration, insulin resistance, and the quality of
glycemic control further complicate attempts to evaluate
associations of any of these risk factors with cognitive
impairment.
Inflammation
Chronic low-grade inflammation is a characteristic
feature of both diabetes and AD and appears to interact
with diabetes in its association with cognitive impairment.
This suggests a common biological mechanism [42]. Cir-
culating markers of inflammation include C-reactive pro-
tein (CRP), interleukin-6 (IL-6), fibrinogen, and tumor
necrosis factor-alpha (TNF-α), some of which have been
associated with cognitive dysfunction in people with dia-
betes (Additional file 1: Table S1). Elevated levels of CRP
have been associated with lower cognitive function in
small studies of hospitalized patients (for example, [9]). In
the ET2DS, higher levels of fibrinogen, TNF-α, and IL-6
but not CRP were associated with lower measures of cog-
nitive function [43, 44]; higher baseline levels of fibrinogen
and IL-6 additionally predicted a steeper 4-year cognitivedecline [45, 46]. CRP levels were also unrelated to cogni-
tive decline in a further prospective study with a 6-year
follow-up [16]. In support of associations (particularly,
causal) between inflammation and cognition, genetic vari-
ants that influence circulating levels of inflammatory
markers have been associated with cognitive impairment,
but this finding has not been consistent [43, 47].
Microvascular disease
Because of the homology between retinal and cerebrovas-
cular cells, the state of small vessels in the retina closely
mirrors that of the cerebral microvasculature, suggesting
that diabetic retinopathy can be used as a marker for the
presence of microangiopathy within the brain. A systematic
review of cross-sectional and prospective observational
studies concluded that people from the general population
and people with diabetes who exhibit retinal microvascular
abnormalities appear to be at increased risk of cognitive im-
pairment, including dementia, compared with people who
have no retinal microvascular abnormalities [48], although
subsequent studies have given conflicting results [25, 35,
49] (Additional file 1: Table S2). However, in support of the
findings of the systematic review, baseline presence of retin-
opathy was recently identified as a predictor of steeper rates
of cognitive decline during 40-month (but not 20-month
intermittent) follow-up in ACCORD-MIND [50]. Overall,
diabetic retinopathy may be a putative surrogate marker
for cognitive impairment in people with diabetes, in which
cerebral microvascular disease may have an important
pathogenetic role.
Macrovascular disease
The prevalence of both symptomatic and asymptomatic
macrovascular disease is increased in people with type 2
diabetes. Given the likely links between vascular and
cognitive pathologies, markers of such vascular ‘end-
organ damage’ have the potential to identify a group of
subjects who are at particularly high risk of developing
cognitive impairment. Assessing the association between
different macrovascular diseases and cognitive impair-
ment may also help us understand underlying patho-
physiological mechanisms. To this end, it is interesting
to consider the extent to which studies have uncovered
associations of cognitive impairment with specific types
of macrovascular disease, such as coronary heart disease
(CHD), cerebrovascular disease, and peripheral arterial
disease, and with vascular biomarkers which indicate
underlying subclinical macrovascular disease in the re-
lated vascular trees.
Coronary heart disease and N-terminal pro-brain natriuretic
peptide
An association of CHD with a lower level of cognitive
function was observed in the ET2DS [51] (Additional file
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the evidence for an association of CHD with cognitive
dysfunction was limited [13], and in all other cross-
sectional investigations [14, 35] and in all prospective
analyses, including the ET2DS [21, 51], the results have
been negative. The only significant prospective association
was in the direction of cognitive ability predicting worsen-
ing of CHD. In ADVANCE, after multivariate adjustment,
a baseline presence of ‘mild cognitive dysfunction’ and ‘se-
vere cognitive dysfunction’ increased the 5-year risk of a
major coronary event by 31 % and 70 %, respectively [35].
The inactive metabolite N-terminal pro-brain natriuretic
peptide (NT-proBNP) is a biomarker of the cardiac stress
associated with ventricular dysfunction and congestive
heart failure. In the ET2DS, an association of small effect
size was found between a higher baseline NT-proBNP and
a lower cognitive ability and with a steeper cognitive decline
later in life [51] (Additional file 1: Table S4). In the general
population and in people with cardiovascular disease,
associations of small to large unadjusted effect size have
been reported relatively consistently between elevated
levels of natriuretic peptide and lower cognitive function
(for example, [52]) and with the presence of dementia or
milder forms of impairment [53, 54]. Null findings are rare
[55] and in some studies may have resulted from the
nature of the cognitive screening instruments that were
applied. Some results have suggested an independence
of these associations from symptomatic macrovascular
disease, including stroke [52], which was also observed
in the ET2DS [51]. Prospective investigations of the
general population were, until recently, restricted to a
single cohort (of people over 75 years of age) in which
the findings were inconclusive [53, 54]. However, a re-
cent large Finnish study (n = 7,000 participants) that
examined the relationship of natriuretic peptides with
cognitive function has not provided definitive evidence
[56]. In that study, each standard deviation above baseline
NT-proBNP predicted a 48 % increased risk of dementia
during 14-year follow-up after multivariate adjustment in
men, but no such association was found in women.Cerebrovascular disease and carotid intima-media
thickness
An association between a lower level of cognitive function
and cerebral infarction has been a consistent finding in
populations with diabetes [13, 51] (Additional file 1: Table
S3). For example, in the Fremantle Diabetes Study, cogni-
tive impairment diagnosed on the basis of a screening in-
strument and follow-up clinical interview was associated
with a history of cerebrovascular disease [14]. The impact
of stroke on cognitive function was demonstrated in the
diabetic subpopulation of a Dutch study and in the ET2DS,
in which an association between stroke and diminishedcognitive function persisted after adjustment for estimated
pre-morbid ability [20, 25, 51].
In the ET2DS and in the Fremantle Diabetes Study, a
history of stroke was associated with a steeper decline in
cognitive ability [14, 51], but this observation differed
from those of several other prospective analyses (for
example, [21]), in which no such association was found.
In the ADVANCE study, evidence of a prospective as-
sociation in the direction of lower cognitive function
predisposing patients to an increased risk of infarction
was observed. After multivariate adjustment, individuals
with ‘mildly reduced’ cognitive function at baseline had a
5-year risk of sustaining a major stroke which was 34 %
greater than that of individuals who had a higher level of
cognitive ability; people with ‘severe cognitive dysfunction’
had a 71 % greater risk [35]. The relationship between
cerebral infarction and cognition in diabetes may therefore
be bidirectional.
In people with type 2 diabetes, greater carotid intima-
media thickness (cIMT) has been associated with a lower
level of cognitive function [9, 11], but its association with
an estimated steeper decline of lifetime cognitive function
has been inconsistent [25, 51] (Additional file 1: Table S3).
To date, the ET2DS appears to be the only prospective
study to examine cIMT and cognition in people with type
2 diabetes. This identified an association of cIMT with a
steeper decline in late-life cognitive function, which was
independent of a preceding history of stroke [51]. In the
population in general, an association between a higher
cIMT and an increased risk of cognitive impairment has
been established [57], and so a similar association is likely
to exist in people with type 2 diabetes.
Peripheral arterial disease and ankle-brachial pressure
index
In people with type 2 diabetes, a low ankle-brachial
pressure index (ABI) - a measure of peripheral arterial
disease (PAD) of the lower limbs and of more generalized
atherosclerosis - and PAD diagnosis have been associated
with lower cognitive function [9, 51] and with dementia
[14] (Additional file 1: Table S3). In the Fremantle Diabetes
Study, 38 % of cognitively ‘normal’ individuals, 45 % of
people with reduced cognitive function, and 75 % of people
with frank dementia had evidence of coexisting PAD [14].
In one study, cross-sectional findings for ‘any vascular
event’ (which was partly defined by PAD) remained signifi-
cant after adjustment for an estimate of peak pre-morbid
ability [20, 25], but after such an adjustment was made in
the analysis of ABI and symptomatic PAD in the ET2DS, it
did not quite achieve statistical significance [51]. However,
in the latter, each standard deviation of a lower baseline
ABI was also associated with a 0.12-standard deviation
increment in subsequent 4-year decline on a composite
measure of cognitive function [51]. In the Fremantle
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dicted an increased risk of cognitive impairment [14]
though it was not associated with the risk of cognitive
decline in the subsequent 2-year follow-up period [21].
Overall, the evidence for an association between
macrovascular disease and cognitive impairment in diabetes
is inconsistent and varies according to the area of the
vasculature considered. As might be expected, evidence
for a relationship with cerebrovascular disease, espe-
cially stroke, is stronger than that for vascular sites
which are more distant from the brain, including the
heart. Evidence for an association with the most distal
presentations of macrovascular disease, such as PAD of
the lower limbs, is particularly limited, is likely to reflect
widespread atherosclerosis as a marker for cognitive im-
pairment in people with diabetes, and would suggest that
any true associations have a small effect size.
Depression and pre-morbid cognitive ability
Depression
Cross-sectional studies of cognitive function in people
with diabetes, with or without depressive symptoms or
clinical depression, have been inconclusive (Additional
file 1: Table S5). One investigation of older people with
type 2 diabetes reported a statistically non-significant
trend for negative correlations between scores on a cogni-
tive screening instrument and scores on a self-administered
screening instrument for depression [58]. In a cross-
sectional analysis of ACCORD-MIND, patients with
depression (based on scores on screening instrument
or on self-report) also scored lower on a cognitive
screening instrument (though not on more detailed
neuropsychological tests) compared with patients who
were free of depression [13]. Additive detrimental ef-
fects have been suggested by another study of people
with type 2 diabetes and healthy controls who were 30
to 80 years of age (the mean age was 60 years across
groups), to whom more detailed neuropsychological
testing was applied along with clinical interviews toFig. 3 Mean difference (95 % confidence interval) in cognitive test scores i
Birth Cohort (1936). Solid lines reflect people without diabetes at age 70; d
permission from Elsevier [62]diagnose depression. The patients with co-morbid diabetes
and depression performed less well on tests of attention
and processing speed compared with participants with
diabetes but without depression. Relative to the latter,
there was also a trend just short of statistical significance
for lower cognitive function overall in the group with
co-morbid diabetes and depression [59]. In a prospective
analysis of a large cohort of Americans, co-morbidities of
diabetes and depression were also linked to a 100 % in-
creased risk of dementia over a period of 3 to 5 years when
compared with people with diabetes but without depression
[60]. Finally, ACCORD-MIND revealed associations of
higher scores on a screening instrument for depression and
a steeper 40-month cognitive decline [61]. In the general
population, the association of depression with cognitive
impairment appears to be well established [60], and so
it seems likely that depression has a contributing role
in promoting diabetes-associated cognitive impairment.
Pre-morbid cognitive ability
Diabetes-associated cognitive impairment may partly re-
flect reverse causality. Consistent with the assumption
that individuals who have lower cognitive ability may be
predisposed to have lower late-life cognitive function
and to be at increased risk of developing diabetes as they
get older, an analysis of the Lothian Birth Cohort (a
group of people who were born in 1936) found that
cross-sectional associations of diabetes with lower late-
life cognitive ability disappeared following adjustment
for cognitive ability that had been measured at age 11
[62] (Fig. 3).
However, where diabetes is associated with a steeper
late-life cognitive decline in prospective analyses, the
role of pre-morbid ability is as yet unclear, particularly
as its role in promoting late-life cognitive decline per se
is uncertain. Some prospective investigations have indi-
cated that individuals with lower cognitive ability decline
more rapidly as they get older [63], but this has not been
confirmed [64].n people with and without diabetes at ages 11 and 70 in the Lothian
ashed lines reflect people with diabetes at age 70. Reproduced with
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The neuropathological features of VaD (multiple in-
farcts) and AD (cerebral plaques of beta amyloid and
hyperphosphorylated tau contributing to neurofibrillary
tangles) [65] are well established. Increasingly, it is being
recognized that there may be considerable overlap in the
etiology of these two conditions [66, 67], and individuals
with cognitive decline often exhibit both pathologies.
Many of the risk factors reviewed in this article have the
potential to contribute to such neuropathology. Clearly,
it is not difficult to conceive how the macrovascular risk
factors in diabetes would contribute to cerebrovascular
damage [12], while chronic hyperglycemia may lead to
the accumulation of advanced glycation end-products in
the brain [68] and the development of small vessel ischemic
change. The neurotoxic effects of hypoglycemia are also
well understood [8], and there are strong links between
insulin and beta amyloid: insulin appears to initiate the
production of beta amyloid as well as promote its accu-
mulation through competition for degradation by
insulin-degrading enzyme [67]; it may further contribute to
amyloid formation through co-secretion of the amyloid-
forming peptide amylin with insulin from pancreatic beta
cells [65, 69]. Consistent with amylin being a neuro-
pathological mediator of associations between diabetes
and cognitive impairment, a recent post-mortem study
demonstrated the presence of the peptide in the brains
of people with diabetes and in those with AD, but not
in healthy controls [69]. Additional associations of
amylin with vascular damage [69] are consistent with
the premise that AD and VaD may not be as clearly dis-
tinct as has been thought previously.
As becomes clear, the neuropathological bases of the
increased risk of cognitive impairment that people with
diabetes are exposed to are far from singular and
straightforward. Rather, highly complex, cell-level pro-
cesses appear to be at play. It is this complexity which
explains the difficulty in the development of effective
strategies for prevention of cognitive impairment in
people with diabetes and in the development of treat-
ment approaches in those patients who have already be-
come cognitively impaired.
Conclusions
Most studies that have addressed the risk factors associ-
ated with cognitive impairment have examined cohorts
from the general population. However, in view of the
greater risk of cognitive impairment affecting people
with type 2 diabetes and the potential differences in
underlying mechanisms between people with type 2 dia-
betes and the general population, more information that
is specific to diabetic populations is required, particularly
in older adults. The evidence that risk factors that occur
more frequently in people with type 2 diabetes areassociated with cognitive impairment is limited, mainly
because few of these risk factors have been investigated
in any depth. Many have also been assessed in isolation.
The evidence that is currently available points to a role
for poor glycemic control, hypoglycemia, micro- and
macrovascular disease, inflammation, and depression as
potential risk factors for cognitive impairment in people
with diabetes. However, the causality in these relation-
ships is less clear. The roles of dyslipidemia, hyperinsuli-
nemia, hypertension, and pre-morbid ability as putative
risk factors are as yet undetermined and require further
investigation. Overall, we would recommend that clini-
cians temper the current emphasis on intensive therapy
and strict glycemic control in an attempt to protect the
cognitive function of their patients (particularly in view
of the potentially detrimental effects that hypoglycemia
may have on cognition). We would encourage them to
take a holistic approach to patient management by ad-
dressing the full range of modifiable risk factors while
being aware of the potential influences of risk factors for
cognitive impairment that are not modifiable.
A previous review of research in this field [70] has indi-
cated that evidence has advanced mainly in a quantitative
manner in recent decades. For modifiable risk factors,
further high-quality and large-scale trials are needed to
determine causality in the interaction between each
major risk factor and their association with cognitive
decline. For glycemic control, future trials should con-
tinue to attempt to separate out the potential duality of
beneficial (reduced blood glucose levels) and detrimental
(hypoglycemia) effects. Rather than using statistical adjust-
ment methods, such as controlling for hypoglycemia
in analyses of anti-diabetes agents and cognitive de-
cline, effects of anti-diabetes agents that do not induce
hypoglycemia could be investigated for that purpose.
Novel directions could also be taken to investigate risk
factors for which the evidence has been largely restricted
to observational studies despite being modifiable. For
instance, trials could determine effects of anti-inflammatory
medication such as non-steroidal anti-inflammatory drugs,
which are already relatively widely used and are low in cost,
in order to provide definitive evidence on potential associa-
tions of these risk factors with cognitive impairment in
people with diabetes as have become apparent from some
observational investigations.
Undoubtedly, large trials are difficult and costly to
conduct, not least because they are resource-intensive,
and for non-modifiable risk factors are not always possible.
As a consequence, cohort studies are likely to continue
dominating this field of research. Harmonization of risk fac-
tor assessments and methodologies between cohorts should
be sought with the aim of enabling integration of a range of
cohorts into single large-scale analyses. Instead of focusing
on individual risk factors with resultant data ‘slicing’,
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among a range of risk factors and should explore their
temporal developments. Specifically, future cohort
studies, including birth cohorts, could use multi-wave
designs to allow statistical procedures such as latent
growth curve modeling to determine the probable
inter-relationships among putative risk factors and es-
tablish their true associations (if any) with cognitive
decline. In view of recent evidence of an association
between cognitive impairment and brain atrophy in
mid-life diabetes [71], the age at which individuals are
recruited for cohort studies may have to be reconsid-
ered to enable a life-course approach to this issue. It is
to be hoped that ongoing and future research will
identify causal risk factors that can be used to develop
preventative interventions and help to identify which
patients are at greatest risk of developing cognitive
impairment.
Additional file
Additional file 1: Tables S1-S5. A summary of the evidence reviewed
in this article on associations of inflammation, microvascular disease,
macrovascular disease, natriuretic peptides and depression with cognitive
function.
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